(Q43420432)

English

Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs

scientific article published in January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 November 2017

Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs (English)

1 reference

Europe PubMed Central

23 November 2017

juvenile rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Wendy J Ungar

1

1 reference

Europe PubMed Central

23 November 2017

Vania Costa

2

1 reference

Europe PubMed Central

23 November 2017

Rebecca Hancock-Howard

3

1 reference

Europe PubMed Central

23 November 2017

Brian M Feldman

4

1 reference

Europe PubMed Central

23 November 2017

Ronald M Laxer

5

1 reference

Europe PubMed Central

23 November 2017

publication date

1 January 2011

1 reference

Europe PubMed Central

23 November 2017

Arthritis Care and Research

1 reference

Europe PubMed Central

23 November 2017

63

1 reference

Europe PubMed Central

23 November 2017

1

1 reference

Europe PubMed Central

23 November 2017

111-119

1 reference

Europe PubMed Central

23 November 2017

Etanercept in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.20337

21 January 2018

Identifiers

10.1002/ACR.20337

1 reference

Europe PubMed Central

23 November 2017

1 reference

Europe PubMed Central

23 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43420432&oldid=1988442475"